Zealand Pharma’s Emmanuel Dulac, fresh from a first US FDA approval for the company’s rescue pen for severe hypoglycaemia in people with diabetes aged 6 years and older, outlines the swift progress that the Danish biotech has made in his two and a half years as CEO. Dulac also highlights the company’s bold ambitions to commercialise five products itself by 2025 and gives some words of advice to other Big Pharma execs considering making the leap to biotech.
After 23 years, we are now building Zealand into a fully integrated independent commercial company and have the right finance, pipeline, and science in place to do so
